Draft a refractory epilepsy pathway: ASM optimization, imaging/EMU,…
- User
Draft a refractory epilepsy pathway: ASM optimization, imaging/EMU, surgery/neuromodulation evaluation, and rescue plans.
- Assistant
Refractory Epilepsy Management Pathway
Draft Version 1.0
Purpose: Structured algorithm for adults/children with drug-resistant epilepsy (DRE), defined per ILAE as failure of adequate trials of ≥2 tolerated, appropriately chosen ASM schedules (monotherapy or in combination) to achieve sustained seizure freedom.
Key Principles:- Multidisciplinary team (neurologist, epileptologist, neurosurgeon, neuropsychologist).
- Patient-centered, shared decision-making.
- Evidence-based (ILAE, AAN/AES guidelines).
- Incorporate SUDEP risk reduction (seizure detection devices, education).
- Reassess at each step; loop back if new data emerges.
Pathway Flowchart (Text-Based)
Start: Suspected/Confirmed DRE ↓ 1. ASM OPTIMIZATION (2-6 months) ↓ (If optimized but seizures persist) 2. DIAGNOSTIC EVALUATION (Imaging/EMU; 1-3 months) ↓ (Seizure focus identified?) ├── YES → 3. SURGERY/NEUROMODULATION EVAL └── NO → Non-lesional workup + Rescue Plans ↓ 4. RESCUE PLANS (Ongoing, integrated at all stages) ↓ Endpoint: Seizure freedom / Palliation / Palliative care1. ASM Optimization (Initial Focus: 2-6 Months)
Goal: Maximize medical therapy before invasive steps.
- History/Review:
Step Actions Adherence & Triggers Confirm compliance (pill counts, apps); address sleep, alcohol, stress, hormones. ASM Audit Document doses, durations, AEs; check levels (e.g., phenytoin, VPA, CBZ). - Optimization Strategy:
- Monotherapy trial of broad-spectrum ASM (e.g., levetiracetam, lamotrigine, topiramate, valproate).
- Rational polytherapy (≤3 ASMs): Synergistic mechanisms (e.g., Na-channel + synaptic vesicle + GABA).
- Precision options: Genetic testing (e.g., SCN1A, mTORopathies); CBD for SCN1A/Dravet.
- Emerging: Cenobamate (titrate slowly, monitor Na), fenfluramine (Dravet/LGS).
- Exit Criteria: No >50% seizure reduction after 2nd/3rd ASM trial → Proceed to Step 2.
- Red Flags: New focal deficit, worsening → Urgent imaging.
2. Diagnostic Evaluation: Imaging & EMU (1-3 Months)
Goal: Localize epileptogenic zone (EZ).
- Non-Invasive:
Modality Indications Protocol MRI All 3T epilepsy protocol (volumetric T1, FLAIR, T2, SWI, DTI). PET (FDG) Non-lesional MRI Interictal hypometabolism. SPECT (ictal/interictal) Localize if MRI/PET equivocal SISCOM analysis. MEG Extratemporal/occipital Spike source localization. Neuropsychological Testing Cognitive mapping Pre-surgical baseline. - Epilepsy Monitoring Unit (EMU):
- Video-EEG (scalp, 3-14 days): Capture 3-5 typical seizures; classify (focal/generalized).
- Safety: 1:1 nursing, seizure response team.
- Withdrawal of 1 ASM if safe to provoke events.
- Exit:
- Lesional (e.g., MTS, FCD) → Surgery eval.
- Non-lesional → Invasive monitoring or neuromodulation.
3. Surgery/Neuromodulation Evaluation (Multidisciplinary Conference)
Goal: Curative (resection) or palliative (neuromodulation) options.
- Pre-Surgical Workup (if concordance):
Procedure Candidates Outcomes (Engel I at 1-2yr) Resective (ATL, TPO) Mesial temporal, frontal 60-80% Laser Interstitial Thermal Therapy (LITT) Deep/hard-to-resect (e.g., insula) 50-65% Invasive EEG (SEEG/SDG) Non-concordant non-invasive Guides resection - Neuromodulation (if non-resectable or multifocal):
Device Indications Efficacy VNS Any DRE (esp. Lennox-Gastaut) 50% responder rate @2yr RNS Focal, 2-16 seizures/month 75% reduction @7yr DBS (ANT) Multifocal 70% reduction @5yr CCS Focal, orbitofrontal/centro-parietal Emerging (~60%) - Conference Decision: Resectable → Surgery. Palliative → Device. Decline → Step 4.
- Post-Op: EMU taper, lifelong ASM (taper if Engel I >2yr).
4. Rescue Plans (Integrated Throughout; Update Annually)
Goal: Abort prolonged seizures (>5min) or clusters/status epilepticus (SE).
- Patient/Emergency Kit:
Tier Agent Dose/Route Max Frequency 1st Rescue Intranasal midazolam (Nayzilam) 5mg (100-140kg); 2.5mg (<50kg) q10min x2 OR Buccal diazepam (Valtoco) 10-20mg age-based q10min x1 2nd Rescue (if 1st fails) Rectal diazepam OR IM midazolam As above Call 911 3rd (Hospital) IV lorazepam → levetiracetam load → propofol/intubate if SE - SE Protocol (RAMPART/Neurocritical Care Society):
- ABCs, BGL, labs.
- Benzodiazepine x2 → 2nd-line ASM (levetiracetam 60mg/kg, fosphenytoin 20PE/kg, valproate 40mg/kg).
- Refractory SE: Infusion (midazolam/ketamine/propofol) + EEG burst suppression.
- Prevention: Wearable detectors (e.g., Embrace2), caregiver training, driving restrictions.
- Palliative: Hospice referral if frequent SE, QoL decline.
Monitoring & Follow-Up
- Quarterly clinic: Seizure diary review, AE screen, QOL (QOLIE-31).
- Annual reassess: New trials (e.g., gene therapy)?
- Metrics: >50% reduction = partial success; aim for Engel I/II.
References: ILAE DRE Definition (2010), AAN Surgical Guidelines (2022), AES Neuromodulation Position (2023).
Next Steps: Pilot in clinic; revise based on audit. Contact for customizations.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.